Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyDaniel J. Wallace, Caroline Gordon, Frédéric Houssiau et al.|Annals of the Rheumatic Diseases|2013Cited by 340
Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?Marilyn C. Pike, Lexy Kelley|Current Rheumatology Reports|2012Cited by 14